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Summary
The appearance of circulating islet-specific autoantibodies before disease
diagnosis is a hallmark of human type 1 diabetes (T1D), and suggests a role
for B cells in the pathogenesis of the disease. Alterations in the peripheral B
cell compartment have been reported in T1D patients; however, to date, such
studies have produced conflicting results and have been limited by sample
size. In this study, we have performed a detailed characterization of the B cell
compartment in T1D patients (n = 45) and healthy controls (n = 46), and
assessed the secretion of the anti-inflammatory cytokine interleukin (IL)-10
in purified B cells from the same donors. Overall, we found no evidence for a
profound alteration of the B cell compartment or in the production of IL-10
in peripheral blood of T1D patients.We also investigated age-related changes
in peripheral B cell subsets and confirmed the sharp decrease with age of
transitional CD19+CD27−CD24hiCD38hi B cells, a subset that has recently
been ascribed a putative regulatory function. Genetic analysis of the B cell
compartment revealed evidence for association of the IL2–IL21 T1D locus
with IL-10 production by both memory B cells (P = 6·4 × 10−4) and islet-
specific CD4+ T cells (P = 2·9 × 10−3). In contrast to previous reports, we
found no evidence for an alteration of the B cell compartment in healthy
individuals homozygous for the non-synonymous PTPN22 Trp620 T1D risk
allele (rs2476601; Arg620Trp). The IL2–IL21 association we have identified, if
confirmed, suggests a novel role for B cells in T1D pathogenesis through the
production of IL-10, and reinforces the importance of IL-10 production by
autoreactive CD4+ T cells.
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Introduction
Type 1 diabetes (T1D) is characterized by the autoimmune
destruction of the pancreatic β cells, primarily by CD4+ and
CD8+ T lymphocytes, resulting in dependency upon exog-
enous insulin [1,2]. In addition to T lymphocytes,
macrophages have also been implicated in β cell death during
the early stages of insulitis, while B cells have been shown to
be one of the most abundant cell types to infiltrate the
inflamed islets during late-stage insulitis [3,4]. Environmen-
tal factors, together with multiple polymorphic alleles of
varying disease risk, determine susceptibility and progression
of the disease [5]. The major histocompatibility complex
(MHC), namely its human leucocyte antigen (HLA) class I
and class II loci, constitutes the strongest known genetic risk
factor for T1D. Candidate gene and genome-wide association
studies have resulted in the identification of more than 45
additional genomic loci associated with disease risk (http://
www.T1DBase.org), and several confirmed susceptibility
genes [6,7]. The identification of four candidate genes
directly involved in B cell receptor (BCR) signalling and B cell
differentiation (PTPN22, BACH2, PTPN2, SH2B3), and three
immunoregulatory cytokine genes (IL10, IL2/IL21, IL27)
involved in the differentiation and function of specific B cell
subsets, implicates a dysregulation in the B cell signalling
pathway in the pathogenesis T1D.
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Although T1D is thought to be predominantly a T cell-
mediated disease, there is increasing evidence for a role of B
cells in the initiation and progression of the disease. In the
non-obese diabetic (NOD) mouse model of autoimmune
diabetes, progression to overt diabetes is reduced in B cell-
deficient mice [8]. The disease phenotype can be rescued
only if B cell-deficient NOD mice are reconstituted with both
bone marrow and B cells, which also leads to the develop-
ment of T cell responses to T1D-specific autoantigens [9].
Furthermore, B cell depletion was also found to abrogate
insulitis and insulin-specific autoimmune responses in NOD
mice [10–12]. In humans, development of multiple disease-
specific anti-islet autoantibodies remains the strongest
known risk factor for the progression to clinical T1D [13],
although it is generally believed that the autoantibodies
themselves are not directly killing β cells through
complement-mediated lysis. The latter assumption is sup-
ported by a lack of genetic overlap between genes and alleles
that predispose to T1D and those that influence autoanti-
body positivity [14,15]. However, while it is clear that loss of
B cell tolerance occurs, little is known regarding defects in
peripheral B cell tolerance that may favour the development
of T1D. One possibility that is commonly discussed is that B
cells act as potent antigen-presenting cells to autoreactive T
cells via sequestration of autoantigens by surface-expressed
immunoglobulins [9,16,17].
Recently, a subset of transitional B cells described by the
CD19+CD27−CD24hiCD38hi phenotype have been referred
to as regulatory B cells, and were characterized by the pro-
duction of the anti-inflammatory cytokine interleukin
(IL)-10 and a dependence on IL-21 signalling [18–22]. This
B cell subset has been suggested to have inhibitory func-
tions in a broad range of autoimmune diseases, such as sys-
temic lupus erythematosus, rheumatoid arthritis, Sjögren’s
syndrome and autoimmune thrombocytopenia [18,19,23].
In T1D, the frequency of CD19+CD10+CD27−CD24hiCD38hi
cells has been reported to be increased in T1D patients, as
well as in non-diabetic carriers of the PTPN22 Trp620
(rs2476601; Arg620Trp) non-synonymous risk allele [24].
PTPN22 is one of the strongest non-HLA genetic risk
factors for T1D, and the non-synonymous Trp620 allele has
been shown previously to impair BCR signalling by altering
Ca(2+) flux in response to B cell stimulation [25]. Moreo-
ver, the Trp620 allele has also been shown to impair periph-
eral and central B cell tolerance, resulting in the
accumulation of autoreactive B cells and up-regulation of
genes involved in B cell activation, such as CD40, TRAF1
and IRF5 [26]. An increased frequency of CD5+ B cells,
another subset which has been ascribed regulatory potential
through the production of IL-10 [27,28], has also been
reported to be increased in T1D patients immediately after
disease diagnosis [29].
In the present study, we employed a comprehensive flow
cytometry approach, using 15 fluorochrome-conjugated
surface markers, to characterize the B cell compartment in
the peripheral blood of T1D patients and healthy individu-
als, and assessed the role of six T1D loci implicated in B cell
function, including the PTPN22 Trp620 non-synonymous
allele, in the regulation of this immune compartment. Fur-
thermore, to investigate whether we could discern a sys-
temic immunoregulatory defect in these patients, we also
assessed the production of IL-10 in purified CD19+ B cells
following IL-21 stimulation, which revealed an association
between polymorphisms of the T1D locus IL2–IL21 and
IL-10 production in memory B cells and, in a follow-up
analysis, in autoreactive T cells.
Materials and methods
Subjects
Adult long-standing (LS) T1D patients (n = 20) and healthy
controls (HC; n = 21) matched for age (within 5-year age-
bands), sex and time of sample preparation were recruited
from the Cambridge BioResource (CBR-http://www.cam
bridgebioresource.org.uk). Newly diagnosed (ND) T1D
patients (n = 25) and unaffected siblings (UAS) of other T1D
probands (n = 25), matched for age, sex and time of sample
preparation, were collected from the JDRF Diabetes–Genes,
Autoimmunity and Prevention (D-GAP) study (http://
paediatrics.medschl.cam.ac.uk/research/clinical-trials/). ND
patients were characterized as having been diagnosed with
T1D less than 2 years ago (with one exception of 42 months)
and UAS were islet autoantibody-negative, and were not
related to any T1D patient included in this study. All donors
were of white ethnicity and all healthy controls were indi-
viduals without autoimmune disease (self-reported).
For the analysis of B cell phenotypes stratified by
PTPN22 genotype, 48 (non-overlapping) additional adult
healthy donors homozygous for the PTPN22 Arg620/Arg620
(n = 24) and Trp620/Trp620 (n = 24) genotypes were recruited
from the CBR. Baseline characteristics for all participating
subjects are summarized in Table 1.
In order to replicate an association of the IL10 genotype
found in B cells, islet antigen-specific IL-10 secretion in
CD4+ T cells was measured in a total of 266 individuals,
including 85 newly diagnosed T1D patients and 181 unaf-
fected siblings recruited from D-GAP.
Ethics
All samples and information were collected with written
and signed informed consent. The D-GAP study was
approved by the Royal Free Hospital and Medical School
research ethics committee; REC (08/H0720/25). Adult long-
standing T1D patients and healthy volunteers were enrolled
into the CBR. The study was approved by the local
Peterborough and Fenland research ethics committee (05/
Q0106/20).
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PBMC sample preparation
Blood volumes taken from each donor ranged between 25
and 50 ml (median volumes of 35 and 32·5 ml for donors
enrolled from CBR and D-GAP, respectively). Peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll
gradient centrifugation and cryopreserved in 10% heat-
inactivated human AB serum in aliquots of 10 × 106 or
5 × 106 PBMCs per vial at a concentration of 10 × 106 cells/
ml, as described previously [30]. Importantly, T1D patients
and healthy controls were recruited contemporaneously and
samples were processed and stored by the same investigators
to prevent spurious findings caused by differential sample
preparation. Median PBMC yields were 42·2 × 106 and
56·7 × 106 for CBR and D-GAP donors, respectively.
Surface immunostainings
Cryopreserved PBMCs (10 × 106) were thawed in a 37°C
waterbath and resuspended in X-Vivo (Lonza, Castleford,
UK) + 1% heat-inactivated, filtered human AB serum
(Sigma, Poole, UK). Cell viability following resuscitation was
assessed in 40 independent PBMC samples using the Fixable
Viability Dye eFluor 780 (eBioscience, San Diego, CA, USA)
and was found to be consistently very high (median = 95·6%;
min = 86·8%, max = 98·2%) for all samples collected as part
of the cohorts analysed in this study.
B cell surface immunostaining was performed on 106
PBMCs using two independent immunostaining panels
(∼750 000 stained with surface panel 1 and the remaining
∼250 000 stained with surface panel 2; see Supporting infor-
mation, Table S1). To reduce the effects of experimental
variation and other potential covariates, PBMC samples
were processed in batches of a minimum of 10 samples per
day. Each T1D patient was paired with one healthy donor
matched for age (within 5-year age-bands), sex and time of
sample preparation. Four T1D patients could not be sex-
matched to a matching control, but as we found no differ-
ences associated with sex they were included in the paired
analyses. One additional adult healthy donor from the CBR
was not matched to a T1D patient and therefore excluded
from the paired association analyses. PBMCs were stained
for 1 h at 4°C with immunostaining panels 1 or 2, respec-
tively (see Supporting information, Table S1).
To assess the reproducibility of the assessed surface
immunostaining phenotypes, we have repeated the meas-
urement of each assessed immune phenotype (with the
exception of CD19+CD5+ B cells) using an independent
PBMC sample from 18 donors, within 1–2 months of the
original measurement.
Cell culture and in-vitro stimulation
CD19+ B cells were purified by magnetic-activated cell
sorting using the human CD19 positive selection kit
(Miltenyi Biotec, Bisley, UK), from 9 × 106 PBMCs and
yielded an average of 300 000 CD19+ cells per donor. Cells
(100 000–150 000 per well) were rested for 30 min at 37°C in
RPMI medium supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and 100 μg/ml Pen-Strep in a
96-well round-bottomed plate (Greiner bio-one, Stonehouse,
UK), and then cultured for 3 days at 37°C with anti-CD40
(200 ng/ml; Biolegend, London, UK), cytosine–phosphate–
guanosine (CpG) (20 nM; InvivoGen, Stockport, UK) and
either IL-21 (1 ng/ml or 100 ng/ml; Gibco, Paisley, UK) or
culture medium alone (unstimulated controls). After 3 days,
samples were activated with 50 ng/ml phorbol myristate
acetate (PMA; Sigma-Aldrich, Poole, UK) and 500 ng/ml
ionomycin (Sigma-Aldrich), 0·67 μl/ml Monensin GolgiStop
(BD Biosciences, Oxford, UK), 1 μM CpG, and 10 μg/ml LPS
(Sigma-Aldrich) for the last 5 h of culture. The higher dose of
IL-21 (100 ng/ml) was found to induce IL-10 production by
the majority of CD19+ B cells (median = 67·0%) and was
therefore not analysed further in this study.
Intracellular immunostainings
After activation, cells were harvested and stained with
Fixable Viability Dye eFluor 780 for 20 min at 4°C. Cells
were then stained with fluorochrome-conjugated antibodies
Table 1. Baseline characteristics of study participants.
Cohort n
Age (years)
Male n (%)
Duration of disease (months) Autoantibody positivity* n (%)
Median Range Median Range Single Multiple
T1D (D-GAP)† 25 13 9–34 16 (64·0) 12 2–42 25 (100%) 22 (88)
T1D (CBR)‡ 20 32 22–42 8 (40·0) 198 6–376 – –
T1D (combined) 45 20 9–42 24 (53·3) 22 2–376 – –
Unaffected relatives (D-GAP) 25 14 10–31 13 (52·0) n.a. n.a. 0 0
Healthy controls (CBR) 21 27 18–37 7 (33·3) n.a. n.a. – –
Healthy controls (combined) 46 18 10–37 20 (43·4) n.a. n.a. – –
Baseline characteristics for the study participants stratified by the study cohorts. *Type 1 diabetes (T1D)-specific autoantibodies: GAD, IA2 and
ZnT8. †Newly diagnosed T1D patients (duration of disease ≤ 3 years) enrolled into the Diabetes – Genes, Autoimmunity and Prevention (D-GAP)
study. ‡Long-standing adult T1D patients enrolled from the Cambridge BioResource (CBR); n.a. = not applicable; – = data not available.
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against surface receptors (see Supporting information, Table
S1) for 1 h at 4°C. Fixation and permeabilization was per-
formed using forkhead box protein 3 (FOXP3) Fix/Perm
Buffer Set (BioLegend) and B cells were then stained with a
phycoerythrin (PE)-conjugated anti-IL-10 or isotype
control antibody (IC) for 1 h at 4°C. Median cell viability
was estimated to be 58·6% (min = 27·5%, max = 82·8%)
following cell culture and in-vitro activation.
All experiments were performed in an anonymized,
blinded manner without prior knowledge of disease state or
genotype.
Flow cytometry
Immunostained samples were analysed using a BD Fortessa
(BD Biosciences) flow cytometer with fluorescence acti-
vated cell sorter (FACS)Diva software (BD Biosciences).
Flow cytometry data were exported in format 3·0 and ana-
lysed using FlowJo (Tree Star, Inc., Ashland, OR, USA).
Compensation controls were generated using CompBeads
(BD Biosciences) compensation beads. Cyto-Cal calibration
beads (Thermo Scientific, Runcorn, UK) were used to assess
instrument stability. Gating strategies, following doublet-
cell exclusion for all assessed immune-cell populations, are
depicted in Fig. 1. Dead-cell exclusion based on the Fixable
Viability Dye was performed for the intracellular
immunostainings.
Detection of β cell-specific IL-10+ CD4+ T cells
Detection of IL-10 production by CD4+ T cells in response
to peptide stimulation was carried out using an enzyme-
linked immunospot (ELISPOT) assay, as described previ-
ously [31,32]. Peptides based on sequences of naturally
processed and presented IA-2 (709-736, 752-775 and 853-
872), proinsulin (C13-32, C19-A3 and C22-A5) and
glutamic acid decarboxylase (GAD)-65 epitopes (335-352
and 555-567), as well as overlapping regions of the insulin B
(1-20; 6-25 and 11-30) and A chain (1-21), were synthesized
by fluorenylmethyloxycarbonyl chloride (Fmoc) chemistry
and purified by high performance liquid chromatography
(HPLC) (Thermohybaid, Ulm, Germany).
All assays were performed blinded to the clinical status of
the donor. Data are expressed as the mean number of spots
per triplicate and compared with the mean spot number in
the presence of diluent alone (stimulation index: SI).
Statistical analyses
Statistical analyses were performed using Prism software
(GraphPad, San Diego, CA, USA) and Stata (http://
www.stata.com). Association of each assessed immune phe-
notype with T1D was calculated using a two-tailed paired
t-test. For IL-10 secretion phenotypes, which showed a
strong right skew that violated the assumption of normality,
the phenotypes were log-transformed before statistical
testing. The effect of covariates, including age (continuous),
sex (categorical), batch number (categorical) and duration
of disease (continuous) on the assessed immune pheno-
types was assessed using linear regression. Association of
the B cell phenotypes with genotype at the six T1D loci
implicated in B cell function was also performed by linear
regression, assuming an additive effect model for the effect
of the minor allele (coded as 0, 1 or 2 according to the
number of minor alleles present) and including age, sex and
batch as covariates. Interaction of age and disease status was
tested by analysis of variance (anova) comparison of linear
regression models allowing either equal or different effects
of age in T1D patients and healthy controls.
Where multiple measurements of IL-10 secretion on
CD4+ T cells after exposure to different peptides were avail-
able from the same individual, we dealt with the resulting
intra-individual correlation within the same regression
framework, but using a robust clustered variance estimator,
with clusters defined by individuals.
For the analysis of the effect of PTPN22 rs2476601
(Arg620Trp), eight samples (three Arg620/Arg620 and five
Trp620/Trp620) showed compromised cell viability after
thawing (>50% dead cells), and were excluded from the
analysis. Exclusion of these eight samples compromised the
paired structure of the original assay design, therefore asso-
ciation of each assessed phenotype with PTPN22 Arg620Trp
genotype was tested using linear regression models in the
remaining 40 healthy donors (21 Arg620 homozygotes and 19
Trp620 homozygotes), including age and sex as covariates.
Significance was assessed with a likelihood ratio test.
To estimate the power of our current study to detect
increasing changes in the mean frequency of CD19+CD27−
CD24hiCD38hi cells between T1D patients and healthy con-
trols, we assumed a reference mean frequency of 5·95% in
controls, as observed in our study, and tested the power to
detect a 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50% increase in
T1D patients. The power calculation was based on a two-
tailed t-test for a sample of 45 T1D patients and 46 healthy
controls at 1 and 5% significance thresholds, and standard
deviations of 2·83 and 3·62 in healthy controls and T1D
patients, respectively, as observed in our study.
We estimated the power to detect a difference in
CD19+CD27−CD24hiCD38hi B cell frequency according to
PTPN22 genotype using the pwr.t2n.test function in the r
[33] package pwr [34]. To estimate our power to replicate
the published association, we assumed a difference per
Trp620 allele of 1·04%, as reported by Habib et al. [24], and a
common standard deviation of 2·05, which is the pooled
estimate of standard deviation reported by Habib et al. [24].
To estimate the number of samples required to confirm the
association if the effect is nearer our estimated effect, we
assumed a per allele difference of 0·415% and a pooled
standard deviation of 1·5.
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Fig. 1. Delineation of peripheral B cell subsets. (a) Gating strategy for the delineation of the seven B cell subsets characterized in this study.
Fluorochrome-conjugated surface markers used for the surface characterization of the subsets are shown in the respective plot. The initial CD19+
gate (CD19 versus side-scatter) was derived from a lymphocyte gate (defined on forward- and side-scatter) followed by single-cell discrimination. (b)
Gating strategy for the characterization of the frequency of interleukin (IL)-10+ cells in total, naive and memory CD19+ populations using an
intracellular immunostaining approach. Plots and frequencies shown in these plots correspond to the delineation of the subsets in one illustrative
individual.
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Results
Delineation of peripheral B cell subsets
Seven major CD19+ B cell subsets were discriminated by
flow cytometry in PBMCs from 91 donors, namely 45 T1D
patients and 46 healthy controls (Fig. 1a and Supporting
information, Table S2). All assessed B cell phenotypes were
found to be highly reproducible in two independent meas-
urements obtained from 18 different subjects (ρ > 0·77;
Supporting information, Table S2). The only notable excep-
tion was the CD19+CD27− immunoglobulin D (IgD)+IgM−
anergic B cell subset (ρ = 0·359; Supporting information,
Table S2), which was therefore not assessed further in this
study. To investigate a putative immunoregulatory defect in
T1D patients, we assessed the frequency of two B cell
subsets with suspected regulatory function, CD19+CD27−
CD24hiCD38hi transitional B cells and CD19+CD5+ (CD5+ B
cells), as well as CD19+CD27+IgD+IgM+ (marginal zone) B
cells. In addition to surface immunophenotyping, we
assessed the intracellular production of IL-10 by total
(CD19+), naive (CD19+CD27−) and memory (CD19+CD27+)
B cells cultured in the presence of IL-21, following in-vitro
stimulation (Fig. 1).
The peripheral B cell compartment in T1D
We first investigated the association of the delineated B cell
phenotypes with T1D using a paired analysis of 45 T1D
patients and 45 healthy donors, matched for age, sex and
time of sample preparation. We found no evidence for a
systematic difference in the frequency of any of the assessed
B cell subsets in T1D patients (Fig. 2 and Table 2). In par-
ticular, we found no difference in the frequency of naive
[P = 0·52, mean of differences = −1·15, 95% confidence
interval (CI) = −4·71 to 2·41] or memory (P = 0·54, mean of
differences = 1·04, 95% CI = −2·38 to 4·46) B cells or in the
two subsets of B cells with a suspected regulatory function,
CD19+CD27−CD24hiCD38hi (P = 0·50, mean of differ-
ences = −0·36, 95% CI = −1·42 to 0·71) and CD5+ (P = 0·25,
mean of differences = 2·34, 95% CI = −1·70 to 6·37) B cells,
previously linked [24,29] with T1D (Fig. 2 and Table 2).
Similarly, we also found no evidence for a variation in the
frequency of these B cell subsets according to the time since
T1D diagnosis (Supporting information, Table S3). Taking
the observed distribution of CD19+CD27−CD24hiCD38hi B
cells in our study as a model, we have > 80% statistical
power to detect alterations of more than 35 and 40% in the
frequency of these cells between patients and healthy
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Fig. 2. The peripheral B cell compartment is not altered in type 1 diabetes (T1D) patients. The frequency of the six B cell subsets robustly
characterized in this study was compared between 45 T1D patients (long-standing and newly diagnosed; depicted by red circles) and 45 healthy
donors matched for age, sex and time of sample preparation (depicted by blue squares). P-values were calculated using a two-tailed paired t-test.
Horizontal bars represent the mean frequency in each genotype group and error bars depict the 95% confidence interval of the mean. Additional
data from the statistical analysis are provided in Table 2.
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controls at a 5 and 1% significance level, respectively
(Fig. 3). Because the distribution of the different B cell
subsets was relatively uniform in our study (Fig. 4), the
power calculations obtained for the CD19+CD27−CD24hi
CD38hi subset can be generalized more broadly for the other
B cell subsets, and suggest that we have only adequate power
to detect changes of > 35–40% in each of the assessed
phenotypes.
Given the dependence of IL-21 signalling on the differen-
tiation of CD19+CD27−CD24hiCD38hi B cells, we also
assessed the surface expression of IL-21R on these B cell
subsets in T1D and healthy controls. However, we found no
evidence of a differential expression of this receptor in T1D
patients in any of the assessed B cell subsets (Table 2).
To investigate a potential immunoregulatory defect in the
B cell compartment of T1D patients, we next assessed the
frequency of IL-10+ B cells by intracellular immunostaining
in magnetically purified CD19+ B cells isolated from the
same donors, and cultured in the presence of IL-21 for 3
days to induce the differentiation of IL-10-secreting
CD19+CD27−CD24hiCD38hi B cells, as described previously
[20]. We found no evidence for a functional difference in
the production of IL-10 in CD19+, naive and memory B
cells isolated from T1D patients compared to healthy con-
trols (Fig. 4 and Table 2), or for an alteration in the produc-
tion of this cytokine according to the duration of the
disease (Supporting information, Table S3).
Age-dependent changes in the composition of the
human peripheral B cell compartment
Age is known to have a strong effect on the differentiation
of the adult immune system. Given the lack of association
of T1D with the assessed B cell phenotypes, we next per-
formed a linear regression analysis, combining all 91 donors
included in this study, to identify age-related changes in the
Table 2. Association analysis of B cell phenotypes with type 1 diabetes (T1D).
Phenotype Pairs (n) P-value Mean of differences (95% CI)
B cell subsets
Total CD19+ B cells 45 0·47 0·70 (−1·24, 2·65)
Naive B cells (CD27−) 45 0·52 −1·15 (−4·71, 2·41)
Memory B cells (CD27+) 45 0·54 1·04 (−2·38, 4·46)
Transitional B cells (CD27−CD24hiCD38hi) 45 0·50 −0·36 (−1·42, 0·71)
Marginal zone B cells (CD27+IgD+IgM+) 45 0·78 0·32 (−1·99, 2·62)
CD5+ B cells 35 0·25 2·34 (−1·70, 6·37)
IL-21R surface expression (MFI)
Total CD19+ B cells 45 0·11 −96·7 (−217·0, 23·7)
Naive B cells (CD27−) 45 0·14 −73·78 (−173·0, 25·4)
Memory B cells (CD27+) 45 0·52 −7·4 (−30·4, 15·6)
Transitional B cells (CD27−CD24hiCD38hi) 45 0·24 89·6 (−61·9, 241·2)
Marginal zone B cells (CD27+IgD+IgM+) 45 0·58 −7·8 (−35·9, 20·3)
CD5+ B cells n.a. n.a. n.a.
IL-10 production*
IL-10+ total CD19+ B cells 40 0·74 0·018 (−0·087, 0·123)
IL-10+ naive B cells 40 0·65 0·025 (−0·086, 0·135)
IL-10+ memory B cells 40 0·73 0·020 (−0·096, 0·136)
P-values were calculated using a two-tailed paired t-test comparing the mean of the B cell phenotypes in T1D patients and healthy donors matched
for age, sex and time of sample preparation. *Statistical tests were performed on log-transformed data because interleukin (IL)-10 phenotypes showed
a strong right skew. CI = 95% confidence interval; MFI = mean fluorescence intensity; n.a. = not applicable.
100
90
80
70
60
50
40
30
20
10
0
0 5 10
Difference between groups (%)
S
ta
tis
tic
al
 p
ow
er
 (
%
)
15 20 25 30 35 40
α = 0·01
α = 0·05
45 50
Fig. 3. Statistical power calculation. Statistical power calculation was
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controls and 45 type 1 diabetes (T1D) patients assessed in this study.
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(α = 0·01; depicted by red squares) or 5% (α = 0·05; depicted by blue
diamonds) significance level. The horizontal dotted line represents the
80% power threshold.
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differentiation of the peripheral B cell compartment. The
frequency of circulating total CD19+ B cells showed a strong
negative correlation with age (ρ = −0·385, P = 1·63 × 10−4;
Fig. 5a and Table 3). This variation corresponded to an
average decrease of 0·21% in CD19+ B cells per year
(Fig. 5a). We also confirmed the significant decrease of
naive (ρ = −0·389, P = 1·40 × 10−4) and the concomitant
increase of memory B cells (ρ = 0·395, P = 1·07 × 10−4) with
age (Fig. 5b,c and Table 3). Consistently, we observed a
negative correlation with age in the two naive B cell subsets
that exhibit suspected regulatory properties – CD5+ B
cells (ρ = −0·428, P = 2·21 × 10−4) and CD19+CD27−CD24hi
CD38hi B cells (ρ = −0·558, P = 9·09 × 10−9), while the
memory subset of marginal zone B cells showed a positive
correlation with age (ρ = 0·339, P = 1·01 × 10−3; Fig. 5d–f
and Table 3). The negative correlation with age was particu-
larly noticeable in CD19+CD27−CD24hiCD38hi B cells, where
age explained more than 31% of the trait’s variance
(R2 = 31·1%). This variation reflected a sharp reduction of
the CD19+CD27−CD24hiCD38hi B cell frequency from an
average 8·7% in individuals aged less than 15 years to 3·7%
in individuals aged more than 30 years, and corresponded
to an average decrease of 0·2% per year (Fig. 5b and
Table 3). The decreased frequency of the peripheral B cell
subsets with age was even more apparent when analysing
the absolute number of B cells in 55 of the 91 donors, where
full blood counts were assessed (Supporting information,
Fig. S1). These data provide a quantitative measure of the
striking age-dependent changes observed in the absolute
numbers of CD19+ cells, and demonstrate that there is a
rapid decline in peripheral B cell numbers with age, which
is particularly pronounced in naive (CD27−) subsets (Sup-
porting information, Fig. S1).
The rate of age-dependent changes did not differ between
T1D patients and healthy controls (Supporting informa-
tion, Fig. S2), indicating that the notable variation in the
frequency of B cell subsets with age is not a consequence of
a disease-specific mechanism, nor is the decline a major
predisposing factor for T1D.
Genetic regulation of the B cell compartment
Among the T1D genomic risk loci identified by genome-
wide association studies, at least six harbour candidate
genes that have been implicated directly in B cell differen-
tiation and function (PTPN22, BACH2, PTPN2, IL2–IL21,
IL10 and SH2B3; http://www.T1DBase.org). To investigate
the potential genetic regulation of the assessed B cell pheno-
types, we tested the association of these traits with the
genetic risk variants in these six loci, taking into account the
strong age-dependent effects observed in this study. This
genetic association analysis was limited by sample size, par-
ticularly for variants with low minor allele frequency. To
account for multiple testing we have therefore used a con-
servative P-value threshold of 1·39 × 10−3, based on a
Bonferroni correction for 36 independent tests, to report
significant association with genotype.
We found no evidence for a major genetic association
with the frequency of peripheral B cell subsets (Table 4).
For IL-10 production by B cells, we obtained evidence for
association of the minor allele at IL2–IL21 (rs2069763
G > T), which confers increased risk for T1D, with
decreased production of IL-10 in memory B cells
(P = 6·4 × 10−4; Table 5). This association equated to a
reduction of 57·8% in the mean frequency of IL-10+
memory B cells in the rare [TT] homozygotes
(mean = 5·09%; n = 11) compared to [GG] homozygotes
(mean = 12·06%; n = 26). To further investigate the role of
genetic variation in the IL2–IL21 locus in the regulation of
IL-10 secretion, we next sought replication of these findings
in an independent data set of CD4+ T cells stimulated with
β cell-specific antigens. We found a consistent association
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Fig. 4. Interleukin (IL-10) production is not affected in B cells from type 1 diabetes (T1D) patients. Frequency of IL-10+ cells in total, naive and
memory CD19+ B cells in T1D patients (n = 40; depicted by red circles) and healthy controls matched for age, sex and time of sample preparation
(n = 40; depicted by blue squares). Frequency of IL-10 secreting cells was determined by intracellular immunostaining in purified CD19+ cells
cultured for 3 days with IL-21 and following stimulation with cytosine–phosphate–guanosine (CpG), lipopolysaccharide (LPS), phorbol-12-
myristate-13-acetate (PMA) and ionomycin. P-values were calculated using a two-tailed paired t-test. Data were log-transformed prior to statistical
testing to correct for a strong right skew affecting the assumption of normality. Horizontal bars represent the mean frequency in each genotype
group and error bars depict the 95% confidence interval of the mean. Additional data from the statistical analysis are provided in Table 2.
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between the rs2069763[T] allele and decreased numbers of
IL-10+ islet antigen autoreactive CD4+ T cells (P = 2·9 × 10−3;
Table 5), which supports a common regulatory mechanism
for the production of this anti-inflammatory cytokine in
both cell types mediated by the rs2069763 polymorphism in
the IL2–IL21 locus. Similarly to the genotype effect
observed in the B cell data set, we found that the association
in autoreactive CD4+ T cells corresponded to a 28·8%
decrease in IL-10+ T cells in [TT] homozygotes (n = 1064)
compared to [GG] homozygotes (n = 335).
In addition to the association with IL2–IL21, we also
observed suggestive evidence for the association of PTPN2,
a gene encoding a protein phosphatase involved in the
negative regulation of the c-Jun N-terminal kinase–signal
transducer and activator of transcription (JAK-STAT) sig-
nalling pathway, with reduced frequency of CD27+IgD+IgM+
marginal zone B cells (P = 3·6 × 10−3; Table 4), although it
just failed to reach our significance threshold.
Association of PTPN22 Arg620Trp with peripheral
B cell subsets
We were initially interested in the association of the T1D-
associated PTPN22 Arg620Trp (rs2476601) non-synonymous
polymorphism because it had previously been associated
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Table 3. Age-dependent changes of peripheral B cell subsets.
Phenotype n P-value
β
(95% CI)
Total CD19+ B cells 91 1·63 × 10−4 −0·21
(−0·31, −0·10)
Naive B cells (CD27−) 91 1·40 × 10−4 −0·50
(−0·74, −0·25)
Memory B cells (CD27+) 91 1·07 × 10−4 0·49
(0·25, 0·73)
Transitional
(CD27−CD24hiCD38hi)
91 9·09 × 10−9 −0·20
(−0·27, −0·14)
Marginal zone B cells
(CD27+IgD+IgM+)
91 1·01 × 10−3 0·25
(0·10, 0·39)
CD5+ B cells 70 2·21 × 10−4 −0·48
(−0·73, −0·24)
Effect of age was calculated using a linear regression model.
β = beta coefficient and 95% confidence interval (CI) of the linear
regression model.
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with the frequency of transitional CD19+CD27−CD24hi
CD38hi B cells in heterozygous healthy donors [24]. To
further investigate the effect of this T1D risk allele, we
assessed the frequency of B cell subsets in an independent
cohort of age-matched 21 Arg620 homozygous and 19 Trp620
homozygous healthy volunteers. We found no difference in
the frequency of the assessed B cell phenotypes between the
two genotype groups (P = 0·39; Fig. 6). This result was con-
sistent with the lack of association of PTPN22 with fre-
quency of transitional CD19+CD27−CD24hiCD38hi B cells
both in the 86 immunophenotyped donors with available
genotype data (P = 0·52; Table 4) or when restricting the
analysis to the 46 non-diabetic donors (25 unaffected sib-
lings and 21 adult healthy controls; P = 0·38). The very low
frequency of Trp620 homozygous donors in the general
population (< 1% in European and European-ancestry
populations) has previously prevented the investigation of
the frequency of CD19+CD27−CD24hiCD38hi cells in Trp620
homozygotes. Importantly, by comparing the mean fre-
quency of CD19+CD27−CD24hiCD38hi B cells in the two
homozygous groups, our data suggest that the estimated
effect size corresponds to an absolute increase of 0·415%
per copy of the Trp620 allele (95% CI = −0·540, 1·371),
assuming an additive effect model, which suggests that any
effect in Trp620 homozygous donors may be lower than
reported previously [24].
Discussion
In this study we have optimized a multi-parametric flow
cytometric approach to characterize the B cell compartment
in the peripheral blood of T1D patients and healthy indi-
viduals. To our knowledge, this is one of the largest studies
to date attempting to characterize this immune compart-
ment comprehensively in humans. We confirmed the previ-
ously reported negative correlation of total B cells with age
[35,36]. In adults, the circulating B cell pool is maintained
by output of cells from bone marrow and division of lym-
phocytes in the periphery, with the relative contribution of
the two processes not well understood [37]. Thus, one likely
cause of the decline in the frequency of total B lymphocytes
with age is a decreased bone marrow output. Consistent
with the observed reduction in the total CD19+ B cell fre-
quency with age, we also observed a sharp decrease of two B
cell subsets with naive properties: CD19+CD27−CD24hi
CD38hi transitional B cells and CD19+CD5+ B cells. These
results are in agreement with previous studies [35,36,38]
and confirm the strong age-dependence in the composition
of these B cell subsets, which are much more abundant
during childhood but decline rapidly thereafter. Interest-
ingly, CD19+CD27−CD24hiCD38hi and CD5+ B cells are two
subsets with suspected regulatory properties via production
of the anti-inflammatory cytokine IL-10 [18,19,27,39]. Such
immune dysregulation resulting from the natural decline of
these regulatory B cell subsets with age may, in fact, be aTa
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Table 5. Genetic regulation of interleukin (IL)-10 production.
B cell subsets*
Genetic locus SNP MAF† Minor allele OR‡ n
IL-10+ naïve B cells IL-10+ memory B cells
P β (95% CI) P β (95% CI)
BACH2 rs11755527 0·429 G 1·13 73 0·72 −0·03 (−0·24 to 0·17) 0·92 0·01 (−0·22 to 0·24)
IL10 rs3024505 0·178 A 0·84 77 0·95 0·01 (−0·24 to 0·25) 0·99 0·00 (−0·27 to 0·27)
IL2–IL21 rs2069763 0·342 T 1·13 75 0·09 −0·16 (−0·36 to 0·04) 6·4 × 10−4 −0·35 (−0·56, −0·14)
PTPN2 rs45450798 0·158 G 1·2 75 0·05 −0·22 (−0·45 to 0·02) 0·18 −0·16 (−0·42 to 0·10)
PTPN22 rs2476601 0·117 T 2·05 77 0·43 0·10 (−0·18 to 0·38) 0·25 0·17 (−0·14 to 0·47)
SH2B3 rs3184504 0·445 T 1·28 74 0·44 −0·07 (−0·28 to 0·13) 0·8 −0·03 (−0·25 to 0·19)
Antigen-specific CD4+ T cells§
Genetic locus SNP MAF† Minor allele OR‡ nº samples P β (95% CI)
IL2–IL21 rs2069763 0·342 T 1·13 2485 2·9 × 10−3 −0·04 (−0·07, −0·02)
Association of the frequency of IL-10+ B cells with genotype at six B cell-related type 1 diabetes (T1D) loci was calculated using a linear regression
model assuming an additive effect model for the effect of the minor allele and including age, sex and batch as covariates. *Statistical tests were per-
formed on log-transformed data because IL-10 phenotypes showed a strong right skew. †Minor allele frequency in the HapMap CEU population.
‡Odds ratio (OR) of the minor allele for the association with T1D (http://www.T1DBase.org). §Analysis of the effect of IL2–IL21 on the production of
IL-10 in CD4+ T cells was obtained in an independent cohort of 266 individuals. Numbers of IL-10+ cells were assessed by enzyme-linked
immunospot (ELISPOT) following stimulation of CD4+ T cells with 12 peptide epitopes from four islet-specific antigens (see Methods for detail).
P-value was calculated on log-transformed data by combining all individual measurements and dealing with the resulting intra-individual correlation
within the same regression framework, but using a robust clustered variance estimator, with clusters defined by individuals. SNP = single nucleotide
polymorphism; MAF = minor allele frequency; β = beta coefficient and 95% confidence interval (CI) of the linear regression model; n = number of
individuals.
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contributing factor to the increased propensity to infec-
tions, prevalence of autoimmune diseases and malignancy
in older individuals [40,41].
In addition to age, we also found evidence for the asso-
ciation of the rs2069763[T] minor allele in the IL2–IL21
locus, conferring increased risk for T1D, with reduced IL-10
production in memory B cells. Importantly, we replicated
this effect in an independent data set of CD4+ T cells stimu-
lated with β cell antigens. These data support a previously
unrecognized functional role of the T1D-associated variant
in this locus in the regulation of IL-10 production in both B
and T cells. It is still unclear which is the causal susceptibil-
ity gene for T1D in this genomic locus, but both cytokines
are known to be highly pleiotropic and play critical roles in
the activation and regulation of the immune system. In
addition to the six B cell-related genetic loci that we tested
in this study, other T1D loci contain candidate genes that
may either play a direct role in B cell function or regulate
the function of another cell type that interacts with B cells.
However, this study was not designed to perform a compre-
hensive investigation of all T1D-associated genetic loci.
Further work will therefore be required to validate not only
the association of IL2–IL21 with IL-10 production, but also
to assess the contribution of additional genetic variants to
IL-10 production in different immune cell-types and under
different IL-10-inducing activation conditions.
Despite this evidence for genetic regulation of the B cell
compartment by a T1D risk locus, we found no evidence
for a significant alteration of the assessed B cell subsets in
T1D patients. Similarly, we did not find any evidence for the
differential production of IL-10 by purified B cells from
T1D patients following in-vitro stimulation with IL-21,
which has been shown recently to drive the differentiation
of IL-10-secreting effector CD19+CD27−CD24hiCD38hi regu-
latory B cells in mice [20]. A limitation of this assay is that
the production of IL-10 is dependent upon the stimulation
and cell culture conditions. In this study, we have replicated
experimental conditions shown previously to induce IL-10
secretion in vitro. However, we cannot exclude the possibil-
ity that T1D-specific alterations in IL-10-producing B cells
could be manifested under different experimental condi-
tions. Furthermore, we have assessed IL-10 production
starting from an initial population of magnetically purified
total CD19+ B cells, which is known to be a heterogeneous
population. T1D-specific alterations in the IL-10 produc-
tion potential could be restricted to only a specific B cell
subset or to a minority of antigen-specific B cells in periph-
eral blood, which would not be identified in these
conditions.
We also observed no differences in the frequency of
CD19+CD27−CD24hiCD38hi B cells between T1D patients
and healthy controls, suggesting that there are no detectable
B cell immunoregulatory alterations in peripheral blood of
T1D patients after disease diagnosis. These results were in
contrast with a previous study, reporting an increased fre-
quency of CD19+CD10+CD27−CD24hiCD38hi B cells in T1D
patients [24]. This increased frequency mimicked the
increase observed in the same study in the frequency of
CD19+CD10+CD27−CD24hiCD38hi B cells in healthy
heterozygotes carriers of the PTPN22 Trp620 allele compared
to homozygous donors for the common Arg620 allele [24].
The B cell subset (CD19+CD27−CD24hiCD38hi) assessed in
our study is comparable with the transitional subset
(CD19+CD10+CD27−CD24hiCD38hi) analysed by Habib
et al. [24]. While we did not use the CD10 marker, previous
findings have reported that CD10 is homogeneously
expressed at high levels in CD19+CD27−CD24hiCD38hi cells
[42]. One potential explanation for the lack of reproducibil-
ity of this finding in our population is a different age distri-
bution of T1D patients and healthy controls (all adults) in
Habib et al. [24] which, given the strong age-dependent
effect in the frequency of CD19+CD27−CD24hiCD38hi cells,
could significantly affect the observed frequencies of this
immune subset.
In our case–control study, sample selection was not based
on PTPN22 Arg620Trp genotype. However, including the
PTPN22 genotype as covariate in our linear regression
analysis did not alter our results (data not shown). To
further investigate the putative role of the non-synonymous
Trp620 allele on the regulation of the CD19+CD27−CD24hi
CD38hi cells we were able to recruit the largest number
(n = 19) of healthy homozygotes for the rare PTPN22 Trp620
genotype to date and age- and sex-matched common Arg620
homozygotes from the Cambridge BioResource. Given the
effect size for one copy of the Trp620 allele reported in Habib
et al. [24], we would have expected to have more than 83%
power to detect a differential frequency of this subset at a
5% significance level in our study, assuming an additive
model for the effect each PTPN22 Trp620 allele. We observed
the same direction of association with increased CD19+
CD27−CD24hiCD38hi cells in Trp620 carriers, but an esti-
mated per-allele effect of 0·415% (95% CI = −0·540 to
1·371) compared to 1·04% in Habib et al. [24]. These results
are consistent with the established phenomenon of ‘win-
ner’s curse’, where estimated effect sizes tend to be inflated
in samples where the effect is first detected. Thus, larger
sample sizes will be required to confirm the putative asso-
ciation of PTPN22 Trp620 with increased CD19+CD27−
CD24hiCD38hi B cell frequency: if the effect is nearer our per
allele estimate, this would require 206 matched PTPN22
Arg620/Arg620 – Arg620/Trp620 pairs at a 5% significance level.
CD19+CD5+ B cells have also been reported to be
increased in T1D patients immediately after disease diagno-
sis (< 30 days after diagnosis) [29]. In our study, we found
no evidence for the increased frequency of CD19+CD5+ B
cells in either newly diagnosed or long-standing T1D
patients compared to healthy controls. However, none of
the T1D patients enrolled in our study were diagnosed
within 30 days and, therefore, our findings are consistent
with the observed lack of differences in CD5+ B cell
W. S. Thompson et al.
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frequency in T1D patients > 30 days since diagnosis
reported by De Filippo et al. [29]. Further studies focusing
specifically at the time of disease onset will be required to
investigate a possible pathogenic role of CD19+CD5+ in the
onset of disease.
Our data indicate that after disease diagnosis there are no
significant changes affecting the delineation of B cell subsets
in peripheral blood, thus illustrating the potential limita-
tion of similar immunophenotyping studies in humans to
robustly identify small phenotypical differences. To circum-
vent or minimize these pitfalls, it is critical to reduce all
sources of technical variation to mitigate systematic batch
effects and ensure the generation of high quality experi-
mental data. In our study, given the observed intra-
individual variation and sample size, we were adequately
powered (80%) to identify changes of 35–40% in the
assessed immune phenotypes. Even for these larger
phenotypical differences, we would have an approximately
20% chance of missing the association in our study design,
which underscores the importance of independent
replicative studies to confirm published observations.
Although we cannot exclude the possibility of smaller
effects our data support that, if present, alterations in
the composition of the peripheral B cell compartment in
T1D patients are subtle and, as a consequence, of limited
utility as a biomarker for the clinical stratification of
T1D patients.
Taken together, our data suggest that there is no obvious
defect in the B cell compartment in the peripheral blood of
T1D patients after disease diagnosis. However, we cannot
rule out a putative role of these subsets in different stages of
disease, namely in the prediabetic stages – most notably at
the time of seroconversion – or at the time of disease diag-
nosis. In addition, our findings are limited to the delinea-
tion of B cell subsets in peripheral blood, as it is the most
accessible source of lymphocytes in humans and, therefore,
we cannot exclude the possibility that local alterations of
specific B cell populations in lymphoid tissues can be impli-
cated in the pathogenesis of the disease. Consistent with this
hypothesis, Rituximab, a B cell-depleting therapeutic anti-
body, has shown some clinical efficacy in T1D in patients
treated within 11 weeks of diagnosis [43]. Clinical efficacy
was restricted to the first 3 months following the initiation
of the treatment course, with a similar decrease in the
C-peptide levels being observed between the treated and the
placebo groups thereafter, although the potential therapeu-
tic effect of repeated treatment courses remains to be estab-
lished. These data suggest that a pathogenic role of B cells in
T1D may be limited to the earlier stages of the disease and
locally in the islets of Langerhans and in the draining pan-
creatic lymph nodes. Moreover, T1D has been shown to
develop in a case-study of a patient with severe B cell defi-
ciency [44], suggesting that B cells are not responsible for
disease pathogenesis in every T1D patient. Other human
autoimmune diseases, including systemic lupus erythe-
matosus, rheumatoid arthritis, Sjögren’s syndrome and
autoimmune thrombocytopenia [18,19,23], have been
linked with a CD19+CD27−CD24hiCD38hi B cell deficiency.
Consistent with this suspected pathogenic role of this subset
in these conditions, diagnosis of these diseases occurs typi-
cally later in life, at a stage where CD19+CD27−CD24hi
CD38hi cell numbers have already declined sharply. In
contrast, T1D is most prevalent among children and
young adults, and the observed decline of CD19+CD27−
CD24hiCD38hi B cells with age does not mirror an increased
risk of T1D, further arguing against a major role of
CD19+CD27−CD24hiCD38hi B cells in the pathogenesis of
the disease.
In contrast to the frequency of circulating B cells, our
data suggest that genetically regulated alterations in the pro-
duction of IL-10 could have a role in the pathogenesis of
the disease. Consistent with this hypothesis, T cell-mediated
antigen-specific responses in T1D patients have been shown
to be polarized to an inflammatory IFN-γ response com-
pared to a regulatory, IL-10-driven response in healthy
donors [31]. Furthermore, a subset of T1D patients with
later disease onset were found to maintain a higher level of
IL-10 secreting CD4+ T cells compared to patients with
more rapid disease onset and progression [45]. These data
support that the balance between proinflammatory, IFN-γ-
mediated and regulatory IL-10-mediated immune
responses could be under the genetic control of disease-
associated loci, including the IL2–IL21 locus, which we have
characterized in this study. To our knowledge, this is the
first evidence showing that genetic regulation of a cytokine
regulates the production of another cytokine located in a
different genomic locus. Genetic studies have implicated
altered IL-2 signalling in the aetiology of T1D [1], and both
memory B cells and activated T cells, where we found evi-
dence for genetic regulation of IL-10 production, express
high levels of the high-affinity IL-2 receptor α-chain (IL-
2RA). In addition, IL-2 signalling through the IL-2RA
receptor has been shown previously to enhance IL-10-
mediated activation of humoral immune responses [46],
suggesting an interaction between IL-2 signalling and IL-10
production. Similarly, IL-21 has been shown to induce
IL-10 mRNA and protein expression in both B [20] and T
cells [47]. Further work will therefore be required to vali-
date this association and, if confirmed, to characterize the
functional mechanisms leading to impaired production of
the anti-inflammatory cytokine IL-10 in individuals carry-
ing the IL2–IL21 T1D risk allele.
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Fig. S1. Age-dependent changes in the absolute number of
B cell subsets. Scatter-plots depict the linear regression of
the effect of age (represented on the x-axis) on the absolute
number of total CD19+ (n = 55) (a), naive CD19+ (n = 55)
(b), memory CD19+ (n = 55) (c), transitional
CD19+CD27−CD24hiCD38hi (n = 55) (d), CD5+ (n = 44) (e)
and CD19+CD27+immunoglobulin (Ig)D+IgM+ marginal
zone (n = 55) (f). B cells (represented on the y-axis) in 55 of
the 91 donors included in this study for whom we had
access to full blood counts. ρ = correlation coefficient.
Fig. S2. Rate of age-dependent changes in the frequency of
B cell subsets does not differ between type 1 diabetes (T1D)
patients and healthy controls. Scatter- plots depict the age-
dependent changes in the frequency of the six assessed B
cell subsets in T1D patients (depicted in red) and healthy
controls (depicted in light green). The linear regression line
is represented for T1D patients and controls. P-values were
calculated by testing the interaction between age and
disease status.
Table S1. Antibodies and immunostaining panels used for
flow cytometry.
Table S2. Reproducibility of the assessed B-cell subsets.
Table S3. Association of the B-cell phenotypes with dura-
tion of disease.
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